1-6 of 6
Tina M Woo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Susan J Lee, Tina M Woo, Shirin Arastu-Kapur, PhD, Alvin F Wong, Pharm.D., Thomas E Renau, PhD, Christopher J Kirk, PhD
Journal: Blood
Blood (2011) 118 (21): 5068.
https://doi.org/10.1182/blood.V118.21.5068.5068
Published: 2011
Journal Articles

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Susan D. Demo, PhD, Monette A. Aujay, BS, Eileen Goldstein, BS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Yan Lu, PhD, Kevin D. Shenk, BS, Congcong M. Sun, MS, Catherine Sylvain, PhD, Tina M. Woo, BS, Hanjie Zhou, PhD, Mark K. Bennett, PhD
Journal: Blood
Blood (2006) 108 (11): 4398.
https://doi.org/10.1182/blood.V108.11.4398.4398
Published: 2006
Journal Articles

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Francesco Parlati, PhD, Monette A. Aujay, B.S., Susan D. Demo, Ph.D., Eileen D. Goldstein, B.S., Jing Jiang, B.S., Christopher J. Kirk, Ph.D., Guy J. Laidig, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Kevin D. Shenk, M.S., Catherine Sylvain, Ph.D., Congcong M. Sun, M.S., Tina M. Woo, B.S., Han-Jie Zhou, Ph.D., Mark K. Bennett, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 4392.
https://doi.org/10.1182/blood.V108.11.4392.4392
Published: 2006
Journal Articles

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Christopher J. Kirk, PhD, Monette A. Aujay, B.S., Mark Ho, B.S., Jing Jiang, B.S., Guy J. Laidig, Ph.D., Evan R. Lewis, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Tina M. Woo, B.S., Congcong M. Sun, M.S., Catherine Sylvain, Ph.D., Jinfu Yang, Ph.D., Han-jie Zhou, Ph.D., Mark K. Bennett, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 3581.
https://doi.org/10.1182/blood.V108.11.3581.3581
Published: 2006
Journal Articles

Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

Owen A. O’Connor, PhD, MD, Robert Z. Orlowski, MD, PhD, Melissa Alsina, MD, Keith Stewart, MBChB, Suzanne Trudel, MD, Marcy K. Vallone, Tina M. Woo, Pedro R. Urquilla, MD, Christopher J. Molineaux, PhD, Andre Goy, MD
Journal: Blood
Blood (2006) 108 (11): 2430.
https://doi.org/10.1182/blood.V108.11.2430.2430
Published: 2006
Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD
Journal: Blood
Blood (2005) 106 (11): 609.
https://doi.org/10.1182/blood.V106.11.609.609
Published: 2005